C. Michael Gibson/cardiometabolichealth.org
Aug 29, 2026, 14:39
C. Michael Gibson: SINGLE-AF Trial Supports DOAC Use in Intermediate-Risk Atrial Fibrillation
C. Michael Gibson, President and CEO at Baim Institute for Clinical Research, Professor of Medicine at Harvard Medical School, Executive Board Member at EXCITE International, shared a post on LinkedIn:
“Single-AF trial: In patients with atrial fibrillation and intermediate stroke risk, DOAC therapy lowered the risk of net adverse clinical events (stroke, systemic embolism, major bleeding, or CV death) compared to no anticoagulation at 24 months.
Download slides here.”
Stay updated with Hemostasis Today.
-
Oct 20, 2026, 06:45Grant Garcia: Why Does a Blood Clot Diagnosis Immediately End an Athlete’s Season?
-
Oct 20, 2026, 06:35Parag Tamhankar: Landmark Study Reveals Genetic Spectrum and Targeted Therapies for ALPS in the Indian Population
-
Oct 20, 2026, 06:26Nina Houben: Neonatal Blood Transfusion Symposium and PhD Defense
-
Oct 20, 2026, 05:46Jan T. Kielstein: DNP Poisoning and Hemoadsorption The Limits of Rescue Therapy
-
Oct 20, 2026, 05:33Giulia Di Paolo: Connecting Plasma Donation to the Patients Who Depend on It
-
Oct 20, 2026, 05:20James Knowles: Exploring Plasma Manufacturing and Strengthening Industry Collaboration
-
Oct 20, 2026, 05:11Giuseppe Lippi։ Understanding Liver Test Abnormalities After AAV Gene Therapy
-
Oct 20, 2026, 05:02Sanam Loghavi: Test Your Hematology Knowledge at ASH 2026!
-
Oct 20, 2026, 04:13Ifeanyichukwu Ifechidere: DOACs Are Not the Answer to Every Anticoagulation Question